Jazz Pharmaceuticals Gets UBS Buy Rating After Strong ASCO 2025 Trial Results

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) ranks among the 30 stocks expected to beat the market by 20 percentage points this year. On June 3, UBS reiterated its Buy rating on Jazz Pharmaceuticals plc (NASDAQ:JAZZ), citing a $164 price target. The update followed a group KOL dinner and speeches at the ASCO 2025 conference, which bolstered their optimism about the company’s future.

Jazz Pharmaceuticals Gets UBS Buy Rating After Strong ASCO 2025 Trial Results

Positive results from a Phase 2 trial that combined zani with chemotherapy for GEA were highlighted by the analysts. The trial’s confirmed objective response rate (cORR) was 83.8% for patients with centrally confirmed HER2+ GEA and 76.2% for all participants. The trial also found that the median overall survival was 36.5 months.

Additionally, UBS analysts spoke with ZYME, a partner of Jazz Pharmaceuticals plc (NASDAQ:JAZZ), on the data read-out schedule. The results of the study were greeted with optimism when management expressed confidence that the data would be accessible by the third quarter of 2025.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is a biopharmaceutical company that develops treatments for serious illnesses. Its key products include Xywav, Xyrem, Epidiolex, Rylaze, Zepzelca, Defitelio, and Vyxeos.

While we acknowledge the potential of JAZZ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

Read More: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds

Disclosure: None.